Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- $850,000
- Closes
- Jan 25, 2027 (in 147 days)
Similar opportunities open now
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses in 49 daysUp to $600K
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 71 daysUp to $150K
- NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses May 2029
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 71 daysUp to $300K
Classification and identifiers
- Solicitation number
- PAR-28-062
- Assistance listing (CFDA)
- 93.399
Amount
$850,000
Who can apply
Small businesses, Local government agencies, and State government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsEligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations.
About this opportunity
This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health (CPACH) Program. The CPACH Program develops and maintains comprehensive, long-term, mutually beneficial partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and addresses challenges in cancer research, including a focus on advancing research on health drivers that contribute to differences in cancer outcomes across all populations, as well as cancer outreach and engagement.